Image via South China Morning Post - Business
Gilead Sciences: Ma Activity
Gilead Sciences agreed to acquire Ouro Medicines for up to $2.18 billion, gaining rights to antibody drug licensed from China's Keymed Biosciences
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: Against a Talent Market Index of 98.6 (Neutral) (down 1.4 month-on-month), Asia is at rising (+2.4pts) on signal share.
Gilead Sciences: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 19 tracked companies; 0.3% of MitchelLake's Asia signal flow; 3 tracked across 62 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
Geographic Expansion · Asia
Thermo Fisher Scientific →Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Capital Raising · Asia
Legend Biotech →First Beijing Investment Ltd acquired $43.78 million stake (2.3M shares) in Legend Biotech, a cancer cell therapy developer
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bristol Myers Squibb →Bristol Myers Squibb partners with China's Hengrui Pharma on a $15.2 billion deal to advance more than a dozen early-stage drugs
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Intelligence powered by Autonodal ↗